Pharsight

Idhifa patents expiration

IDHIFA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9512107 BRISTOL MYERS SQUIBB Therapeutically active compositions and their methods of use
Jan, 2033

(8 years from now)

US10093654 BRISTOL MYERS SQUIBB Therapeutically active compounds and their methods of use
Aug, 2034

(10 years from now)

US9738625 BRISTOL MYERS SQUIBB Therapeutically active compounds and their methods of use
Aug, 2034

(10 years from now)

US9732062 BRISTOL MYERS SQUIBB Therapeutically active compounds and their methods of use
Sep, 2034

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610125 BRISTOL MYERS SQUIBB Methods and compositions for cell-proliferation-related disorders
Jun, 2030

(6 years from now)

US10294215 BRISTOL MYERS SQUIBB Therapeutically active compounds and their methods of use
Jan, 2033

(8 years from now)

Idhifa is owned by Bristol Myers Squibb.

Idhifa contains Enasidenib Mesylate.

Idhifa has a total of 6 drug patents out of which 0 drug patents have expired.

Idhifa was authorised for market use on 01 August, 2017.

Idhifa is available in tablet;oral dosage forms.

Idhifa can be used as treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation.

Drug patent challenges can be filed against Idhifa from 01 August, 2021.

The generics of Idhifa are possible to be released after 16 September, 2034.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-151) Aug 01, 2024
Orphan Drug Exclusivity(ODE) Aug 01, 2024
New Chemical Entity Exclusivity(NCE) Aug 01, 2022

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ENASIDENIB MESYLATE ingredient

NCE-1 date: 01 August, 2021

Market Authorisation Date: 01 August, 2017

Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation

Dosage: TABLET;ORAL

More Information on Dosage

IDHIFA family patents

Family Patents